Accelerating Molecules to Medicines: A Leader’s Blueprint for Pharma

Synopsis: With drug development timelines stretching toward a decade, the pharmaceutical industry faces growing pressure to rethink how medicines are made. Drawing on decades of industry experience, Dr Chris H. Senanayake, Founder and CEO of TCG GreenChem, is driving a greener, faster, and more integrated model for turning molecules into medicines.

For more than 35 years, Dr Senanayake has been at the forefront of pharmaceutical science and green chemistry. From Dow and Merck to Sepracor and Boehringer Ingelheim, he has played a pivotal role in the sustainable green manufacturing processes of hundreds of complex APIs in the advancement of the pharmaceutical pipeline including, multi-billion-dollar medicines such as Crixivan, Lunesta, Jardiance, RR Formoterol and Desvenlafaxine. That track record alone would define an exceptional career. What sets him apart, however, is how he has used that experience to reimagine how the entire drug-development journey can (and should) work.

From Blockbuster Chemist to Visionary CEO

Trained as a synthetic organic chemist specialising in the assembly of architecturally complex molecules, Dr Senanayake quickly built a reputation as the person companies turned to when a process seemed impossible. At Merck, he received the prestigious Merck Management Award for his work converting Compactin into Mevacor (lovastatin), extending the lifecycle of a blockbuster cholesterol drug.

At Sepracor, his entrepreneurial mindset helped scale the company from 70 to more than 1,000 employees in six years. He later spent over 16 years at Boehringer Ingelheim Pharmaceuticals as Vice President of Chemical Development (US), directing North American process chemistry, CMC strategy and technology transfer for global manufacturing. During that time, his teams accelerated the development of Jardiance, which generated over $3.2 billion in sales in 2019 alone, reaching $9 billion for the year 2024.

Across his career, Dr Senanayake has authored more than 500 scientific publications, holds 150+ patents, and has an H-index of 75, alongside serving on editorial boards and becoming a recognised authority in asymmetric synthesis, catalysis and scalable green chemistry.

Yet despite these achievements, he observed persistent structural problems in drug development: siloed teams, fragmented data, late-stage surprises and insufficient integration of sustainability. These insights would ultimately shape his next chapter.

Building a New Kind of Organisation

TCG GreenChem, Inc. is Dr Senanayake’s response. Founded as part of The Chatterjee Group, the company is deliberately designed as an integrated CDMO and Contract Innovator Organisation — one that co-designs the smartest, most sustainable pathway from molecule to medicine.

Its vision is to catalyse the development of novel, effective and affordable medicines for patients with unmet needs. Its mission: to integrate frontier science, advanced technologies and global talent through green chemistry; truly “Accelerating Molecules to Medicines.”

From day one, TCG GreenChem applies a first-time-right philosophy. Cross-functional teams consider route design, impurity and polymorph control, solid-state behaviour of APIs and scale-up feasibility at the earliest stages. Platform technologies, including catalysis, continuous flow chemistry, microfluidics, electrochemistry and automated reaction design, are deployed not as buzzwords, but as practical tools to reduce steps, enhance safety and shorten timelines.

Green Chemistry as a Strategic Engine

Long before sustainability became a boardroom priority, Dr Senanayake championed green chemistry as both scientific best practice and ethical responsibility. His pioneering work earned him the Swiss Siegfried Gold Medal Award, one of the highest international honours in process chemistry, including recognition for the first large-scale macrocyclic ring-closing metathesis run at high concentration with low catalyst loading for architecturally complex HCV drug candidate.

At TCG GreenChem, green chemistry is embedded into every programme. The company applies the 12 Principles of Green Chemistry, prioritising step economy, atom economy, redox economy and emphasis on “Ideal Synthesis.” Hazardous reagents are minimised, routes are shortened, and technologies such as biotransformation, and continuous flow chemistry to reduce waste, low solvent usage and efficient energy consumption.

This is not greenwashing, but rigorous process optimisation and sustainability. Clients benefit from safer, more robust and often lower-cost processes, while regulators and society benefit from reduced environmental impact. It is precisely this fusion of sustainability and practicality that the Global Visionary Leader award seeks to recognise.

A Global Engine Bridging the US and India

TCG GreenChem’s structure reflects Dr Senanayake’s deep experience running international organisations. Its Innovation Centre in New Jersey focuses on high-end process R&D, CMC strategy and early clinical supply, working closely with clients and regulators.

These efforts connect seamlessly to the large-scale CRAMS and CDMO capabilities of TCG Lifesciences in India, where Dr Senanayake also serves as Chief Scientific Officer, alongside strategic cGMP partners across Asia and Europe. Collaborations include leaders in new modalities, such as Indena in the ADC space and partners in peptides.

This model enables complex intermediates and APIs to be conceived and de-risked under direct scientific oversight in the US, then transferred into robust, scalable manufacturing offshore — all within harmonised quality and regulatory frameworks. For sponsors, this means faster technology transfer, resilient supply chains and globally competitive economics.

Turning 1,300 Scientists into One Team

Across TCG GreenChem and TCG Lifesciences, more than 1,300 scientists work under a shared vision. Dr Senanayake’s focus is not just scale, but coherence. Drawing on decades of leadership experience, he builds cross-functional, end-to-end teams that integrate chemists, analysts, engineers, solid-state experts and regulatory specialists from the outset.

Knowledge sharing is systematic, platforms are shared, and learning moves quickly across programmes and sites. Central to this approach is servant leadership — a style grounded in mentoring, openness and leading from the lab as much as the boardroom. Scientists are encouraged to publish and engage with academia, while clients experience a partner that is collaborative, curious and deeply invested in success.

Innovation with Real-World Impact

The results are tangible. In one recent late-stage small-molecule programme overseen personally by Dr Senanayake, a complex API with a fragile impurity profile was redesigned using his Ideal Synthesis philosophy. By integrating innovative catalysis and continuous flow, the team delivered a shorter, higher-yielding and safer process. Hazardous steps were moved into flow, impurity control tightened, and the sponsor reached Phase I supply ahead of schedule at lower cost, with a stronger process-patent position.

More broadly, TCG GreenChem has supported multiple partners in advancing New Chemical Entities to the clinic. Notably, its work with Kura Oncology contributed to the development and late-2025 approval of ziftomenib (Komzifti) — clear evidence that its integrated model can turn cutting-edge science into commercial reality.

Navigating a New Regulatory and Supply-Chain Era

Post-2020, regulators and policymakers have placed renewed emphasis on quality, resilience and security of supply. Few leaders are better prepared than Dr Senanayake. At Sepracor and Boehringer Ingelheim, he supported global clinical supply and major regulatory filings.

At TCG GreenChem, this experience translates into proactive regulatory surveillance, harmonised quality systems and development strategies designed to anticipate evolving requirements. The company’s diversified global footprint enables rapid technology transfer, resilient sourcing and mitigation of geopolitical risk, reinforced by partnerships focused on reshoring critical medicines to the United States.

A Template for Science-Led Growth

In recent years, Dr Senanayake has also been recognised as a business leader, with honours including Best CEO in the Pharmaceutical Industry – North America, Growth Strategy CEO of the Year – USA, and inclusion among the Top 20 Dynamic CEOs.

Asked what others can learn from TCG GreenChem’s trajectory, he highlights three principles: start with the patient and partner, not the project plan; invest equally in people and platforms; and treat culture as foundational. Servant leadership, ethical practice and sustainability are not soft ideals — they are the enablers of innovation, compliance and commercial success.

Looking Ahead

As complexity and expectations rise across healthcare, Dr Chris H. Senanayake’s integrated, green, data-driven iCDMO model offers a compelling blueprint. For patients, it promises earlier access to safer, more affordable therapies. For companies, it demonstrates how scientific excellence, sustainability and business performance can be aligned, proving that when vision, experience and values converge, we truly can accelerate molecules to medicines.